Exact Sciences CORP: insider trades · United States · SEC (Form 4)

About Exact Sciences CORP

Exact Sciences Corp. is a U.S.-based company listed on the Nasdaq (EXAS) in the United States. Headquartered in Madison, Wisconsin, the company focuses on cancer screening, early detection, and precision oncology diagnostics. Founded in 1995, Exact Sciences has evolved from a niche molecular diagnostics player into one of the better-known names in oncology testing, building its franchise around non-invasive screening, clinical validation, and physician decision support. The company’s business is organized around two main pillars: Screening and Precision Oncology. In Screening, Exact Sciences is best known for Cologuard, its at-home colorectal cancer screening test, which has become the company’s flagship product and a key driver of brand recognition. More recently, the company launched Cancerguard, a multi-cancer early detection blood test available in the United States as a laboratory-developed test. In Precision Oncology, Exact Sciences markets Oncotype DX, a genomic test designed to help clinicians assess recurrence risk and guide treatment decisions in certain breast cancer settings. The portfolio is supported by ongoing clinical studies, biomarker development, and a broader innovation pipeline aimed at improving cancer detection and treatment guidance. From a competitive standpoint, Exact Sciences holds a meaningful position in the fast-growing cancer diagnostics market. Its competitive advantages include strong clinical evidence, established physician awareness, reimbursement relationships, and a recognized consumer-facing brand in colorectal screening. At the same time, the business operates in a highly competitive and regulated environment, where adoption depends on clinical utility, payer coverage, and continued evidence generation. The company’s geographic footprint remains primarily centered in the United States, although management has pointed to longer-term international opportunities. Recent developments are especially important for investors. In February 2026, Exact Sciences reported record full-year 2025 results, with revenue growth and improved cash generation. In September 2025, it launched Cancerguard in the U.S., adding a new platform in multi-cancer early detection. In November 2025, Exact Sciences announced a definitive merger agreement with Abbott Laboratories, a major strategic event that could materially change the company’s ownership structure and future operating profile. Overall, Exact Sciences looks like an innovative U.S. healthcare diagnostics company with strong exposure to the structural growth of cancer screening and precision medicine.